+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.

Age: 18Years - 75YearsAll GendersPhase 3
77 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a new drug called TQB2102 for Injection compared to a combination treatment of docetaxel, trastuzumab, and pertuzumab in adults with HER2 positive recurrent or metastatic breast cancer. This Phase III trial involves multiple centers and randomizes participants into two groups to compare these treatments. The study aims to better understand how well TQB2102 works and its safety profile in this patient population. Participants receive treatments through intravenous infusions every 21 days. One group is treated with TQB2102, a next-generation HER2 Antibody-Drug Conjugate, while the other group receives docetaxel combined with trastuzumab and pertuzumab following specific dosing schedules. Docetaxel is given once every three weeks for six cycles, trastuzumab starts with a loading dose followed by maintenance doses every three weeks, and pertuzumab is administered with an initial loading dose followed by maintenance doses every three weeks with observation after infusions. The study compares these two treatment approaches over the course of the trial. During the study, participants will undergo regular evaluations including imaging to assess tumor response, blood tests to monitor drug levels and immune responses, and tracking of any side effects or adverse events. The primary outcomes measured are the objective response rate and progression-free survival up to about 30 months. Secondary outcomes include overall survival, duration of remission, and detailed safety assessments up to around 52 months. The study also involves monitoring specific antibodies related to the drug and other laboratory markers to understand treatment effects fully.

Age: 18Years - 75YearsAll GendersPhase 3
25 locations
R

Actively Recruiting

Researchers are evaluating whether a subtype-based active video education program can improve the quality of bowel preparation for patients with inflammatory bowel disease IBD undergoing colonoscopy. This multi-center, randomized controlled trial involves 600 patients with ulcerative colitis or Crohns disease across 13 hospitals in China. The study aims to compare the addition of tailored video education to standard bowel preparation education and measure its impact on bowel cleansing quality using the Boston Bowel Preparation Scale BBPS. Participants are randomly assigned to one of two groups the intervention group receives conventional education plus subtype-specific active video education delivered via WeChat, which they must watch at least once within three days before colonoscopy the control group receives standard written and verbal bowel preparation education only. The study does not involve any investigational drugs or devices. Randomization is stratified by center, and outcome assessors are blinded to group assignments to reduce bias. Participants will be monitored during colonoscopy to assess bowel preparation quality, cecal intubation rates and times, patient compliance, knowledge, anxiety, satisfaction, and adverse events up to seven days post-procedure. Data will be collected on compliance and patient experience on the day of colonoscopy. Statistical analyses will account for center effects, and the study is expected to complete by October 2026.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
12 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
P

Actively Recruiting

Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.

Age: 18Years +All GendersPhase 3
149 locations
A

Actively Recruiting

Researchers are conducting a prospective, multi-center observational study in China to better understand drug-induced liver injury DILI. The study aims to explore the clinical features, identify the drugs or herbs causing DILI, assess patient outcomes, and discover new serum markers. The goal is to develop and validate a prognostic model incorporating these novel markers to improve prediction of patient prognosis in China. Participants will be grouped into a modeling group to help build a predictive model for DILI outcomes, and a validation group to test the accuracy of this model. The study collects long-term data to establish and verify these prognostic tools. No experimental treatments are given as this is an observational cohort study. During the study, researchers will monitor participants for key outcomes such as death, liver transplantation, and acute liver failure over one year, as well as chronic DILI and recovery over two years. Data will be collected through regular clinical assessments and laboratory tests. This long-term follow-up will help improve understanding of DILI prognosis and validate new serum biomarkers. Participants will be involved over extended periods to ensure comprehensive outcome measurement.

Age: 18Years +All Genders
13 locations
E

Actively Recruiting

Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.

Age: 18Years +All GendersPhase 3
679 locations
T

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.

Age: 18Years +All GendersPhase 3
594 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
E

Actively Recruiting

Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.

Age: 18Years - 80YearsAll GendersPhase 3
61 locations

1-10 of 25

1